

Opportunities for Improving Achievement of Quality Measures in Patients With Type 2 Diabetes Mellitus

This supplement to *The American Journal of Managed Care* reports the results of 2 studies evaluating quality measure attainment in type 2 diabetes mellitus (T2DM). The first study evaluates the potential financial implications of quality measure attainment in patients with T2DM. The second study reports a post hoc analysis of a randomized controlled clinical trial evaluating the quality measure attainment of patients treated with either canagliflozin 300 mg/day or sitagliptin 100 mg/day in addition to metformin and sulfonyleurea. Although further research is necessary, these results may help managed care organizations evaluate the value of improving quality measures associated with T2DM.

■ Faculty

Robert A. Bailey, MD

Director
Health Economics and Outcomes Research
Janssen Scientific Affairs, LLC
Raritan, New Jersey

Lawrence Blonde, MD

Director
Ochsner Diabetes Clinical Research Unit
Department of Endocrinology
Ochsner Medical Center
New Orleans, Louisiana

C. V. Damaraju, PhD

Director
Medical Affairs, Biostatistics
Janssen Research & Development, LLC
Raritan, New Jersey

Mei Sheng Duh, MPH, ScD

Managing Principal
Analysis Group, Inc
Boston, Massachusetts

Lawrence Garber, MD

Medical Director for Informatics
Reliant Medical Group
Worcester, Massachusetts

Jonathan Gravel, MSc

Economist
Groupe d'Analyse, Ltée
Analysis Group, Inc
Montreal, Quebec, Canada

Amanda M. Grittner, MA

Economist
Groupe d'Analyse, Ltée
Analysis Group, Inc
Montreal, Quebec, Canada

Marie-Hélène Lafeuille, MA

Senior Economist
Groupe d'Analyse, Ltée
Analysis Group, Inc
Montreal, Quebec, Canada

Patrick Lefebvre, MA

Vice President
Groupe d'Analyse, Ltée
Analysis Group, Inc
Montreal, Quebec, Canada

Silas C. Martin, MS

Director
Health Economics and Outcomes Research
Janssen Scientific Affairs, LLC
Raritan, New Jersey

Gary E. Meininger, MD

Vice President, Franchise Medical Leader
Janssen Research & Development, LLC
Raritan, New Jersey

Marcia F. T. Rupnow, PhD

Senior Director
Health Economics and Outcomes Research
Janssen Scientific Affairs, LLC
Raritan, New Jersey

■ **Faculty Disclosures**

These faculty report relationships with the following organizations:

Robert A. Bailey, MD

Employment:

Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Stock ownership:

Johnson & Johnson

Lawrence Blonde, MD

Grant/research support:

Eli Lilly and Company; Novo Nordisk; Sanofi

Consultant:

Amylin Pharmaceuticals, Inc; Eisai; GlaxoSmithKline; Janssen Pharmaceuticals, Inc;
Merck & Co, Inc; Novo Nordisk; Pfizer; Sanofi; Santarus

Lecture fees:

Amylin Pharmaceuticals, Inc; Bristol-Myers Squibb/AstraZeneca; Janssen Pharmaceuticals, Inc;
Johnson & Johnson Diabetes Institute, LLC; Merck & Co, Inc; Novo Nordisk; Sanofi; Santarus;
Vivus, Inc

C. V. Damaraju, PhD

Employment/stock ownership:

Janssen Research & Development, LLC

■ PARTICIPATING FACULTY ■

Mei Sheng Duh, MPH, ScD

Employment:

Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc)

Jonathan Gravel, MSc

Employment:

Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc)

Amanda M. Grittner, MA

Employment:

Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc)

Marie-Hélène Lafeuille, MA

Employment:

Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc)

Patrick Lefebvre, MA

Employment:

Analysis Group, Inc (recipient of grants from Janssen Pharmaceuticals, Inc)

Silas C. Martin, MS

Employment:

Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Stock ownership:

Johnson & Johnson

Gary E. Meininger, MD

Employment:

Janssen Research & Development, LLC

Stock ownership:

Johnson & Johnson, Merck & Co, Inc

Marcia F. T. Rupnow, PhD

Employment and meeting/conference attendance:

Janssen Scientific Affairs, LLC (a Johnson & Johnson company)

Stock ownership:

Johnson & Johnson

Lawrence Garber, MD, reports no relationship or financial interest with any entity that would pose a conflict of interest with the subject matter of this supplement.

Signed disclosures are on file at the office of *The American Journal of Managed Care*, Plainsboro, New Jersey.

Opportunities for Improving Attainment of Quality Measures in Patients With Type 2 Diabetes Mellitus

This supplement was supported by **Janssen Pharmaceuticals, Inc.**

The contents of this supplement represent the work of the authors.

The contents of this supplement may include information regarding the use of products that may be inconsistent with, or outside of, the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.

• • •

Opinions expressed by authors, contributors, and advertisers are their own and not necessarily those of Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, the editorial staff, or any member of the editorial advisory board. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, is not responsible for accuracy of dosages given in articles printed herein. The appearance of advertisements in this publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality, or safety. Clinical Care Targeted Communications, LLC, d/b/a Managed Care & Healthcare Communications, LLC, disclaims responsibility for any injury to persons or property resulting from any ideas or products referred to in the articles or advertisements.